News of Note—Gardasil-Cervarix divide, flu vaccines and more

newspapers
(Pixabay)

Here is some other vaccine news of note for the week:

> Starting from this fall, students in Quebec are receiving one shot of Merck & Co.’s Gardasil 9 and then later a shot of GlaxoSmithKline’s Cervarix to protect against HPV. Experts worry the new program will not build sufficient immunity to seven of the nine strains not covered in Cervarix. The Globe and Mail article

> Italy’s health minister, Giulia Grillo, from the vaccine-skeptic party Five Star Movement, has sacked the entire board of the country’s health advisory committee. The Guardian article

Survey

Veeva 2020 Unified Clinical Operations Survey

We believe you have the knowledge and expertise to make this year's Veeva 2020 Clinical Operations Report even more robust and insightful than the last. Please take a moment to share your opinion in this 10-minute survey. All qualified respondents will be entered to win a $500 Amazon gift card.

> An ongoing shortage of GlaxoSmithKline’s popular shingles vaccine, Shingrix, has caused frustration among people waiting to get it. The Boston Globe article

> About 60% of people 60 and older in the U.S. have gotten a flu shot this season, according to new data from Clover Health. UPI article

> The global vaccines market is expected to reach $57.5 billion by 2025, up from from $33.7 billion in 2018, according to a report from Meticulous Research. Release

Suggested Articles

Pfizer posted positive top-line results for a trial of its 20-valent pneumococcal vaccine, potentially setting up a filing by the end of 2020.

Univercells's new CDMO, Exothera, is hoping to play a role in helping drugmakers scale up manufacturing for a possible COVID-19 vaccine.

CanSino and its partners won a go-ahead to move a recombinant coronavirus vaccine into phase 1 testing in Wuhan, China, once the outbreak's center.